M. Jacques Chirac, President of France, received A.F.M members at the Elysée Palace.
On December 4th, the President of the French Republic, Mr. Jacques Chirac, received at the Elysée Palace, the members of French Association against Myopathies and some of the researchers working in the field of myopathologies as Dr. Jacques P. Tremblay. At this occasion, Mr. Jacques Chirac supported the action of French Association against Myopathies and gave his entire support to the research financed by the donations to the Telethon.
Dr Jacques P. Tremblay elected personality of the week by the La Presse journal and RDI.
On the 22nd of October 2006, the Press journal and RDI channel have awarded Dr. Jacques P. Tremblay the personality of the week title for his work on Duchenne Muscular Dystrophy.
Dr Jacques P. Tremblay received the Henry-Friesen 2006 award
The Henry Friesen award was presented to Dr Jacques P. Tremblay by the Royal College of Physicians and Surgeons of Canada and the Canadian Society for Clinical Investigation for his sustained work on Duchenne Muscular Dystrophy.
Autorisation of Canada Health to proceed to a 2nd clinical trial
Following the publication of encouraging results of the phase 1 clinical trial, Canada Health authorizes Dr. Jacques P. Tremblay to carry out a second clinical trial. The purpose of the clinical trial of phase 1 was to show the effectiveness of the transplantation of healthy muscle precursor cells in 1 cm3 of a patient dystrophic muscle. This test showed the restoration of dystrophin in the muscle fibers of 8 out of 9 patients. The second clinical trial will consist in transplanting muscle precursor cells throughout a muscle . The research team is currently looking for Canadian DMD or BMD patients 18 years old or older to participate to a second clinical trial. The clinical trial purpose is to transplant a whole arm muscle with muscle precursor cells. Interested patients should ask their neurologist or directly contact
The Jacques P. Tremblay team received the Syrius award.
The award was presented by the CHUQ to the Jacques P. Tremblay team in recognition for the clinical study conducted on nine DMD patients (pubmed link).
Dr Jacques P. Tremblay appointed Researcher of the year in Canada
Following the publication of the phase 1 clinical trial encouraging results, Muscular Dystrophy Canada awarded Dr. Tremblay the title of Researcher of the year 2005 for this success.
Dr Jacques P. Tremblay appointed Researcher of the year in Quebec by Muscular Dystrophy Canada
Muscular Dystrophy Canada named Dr. Tremblay Researcher of the year 2004 for the Quebec province for the encouraging results obtained by his laboratory following the transplantation of muscle precursor cells to 3 DMD patients.
Phase 1 clinical trial result announcement
The preliminary results obtained in 3 DMD patients were conclusive. One month after the injection of healthy muscle precursor cells, the dystrophin protein was detected in the muscle fibers of the patients. These results showed for the first time the effectiveness of this cell therapy to restore the expression of dystrophin in the muscle fibers of young DMD patients.